NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"),
a leading biotech company developing psychedelic-inspired
therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific
Advisory Board.
Dr. Oquendo is Ruth Meltzer Professor and Chairman of Psychiatry
at University of Pennsylvania and
Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania. A summa cum laude
graduate of Tufts University, she
attended Vagelos College of Physicians and
Surgeons at Columbia University. She completed residency at
the Payne Whitney Clinic of New York Hospital Cornell. She is a
member of the National Academy of Medicine, one of the highest
honors in medicine.
Dr. Oquendo has used Positron Emission Tomography and Magnetic
Resonance Imaging to map brain abnormalities related to mood
disorders and suicidal behavior. She has over 450 peer-reviewed
publications and an h-factor of 78, with over 18,000 citations.
Dr. Oquendo is Past President of the American Psychiatric
Association (APA), the International Academy of Suicide Research,
and the American College of Neuropsychopharmacology (ACNP). She is
Vice President of the Board of the American Foundation for Suicide
Prevention, Vice President of the College of International
Neuropsychopharmacology, and has served on the National Institute
of Mental Health's Advisory Council.
Dr. Oquendo is a member of Tufts
University's Board of Trustees and serves on its Executive
Committee. A recipient of multiple awards in the US, Europe and South
America, most recently, she was honored with the
Alexandra Symonds Award (APA 2017),
the APA's Research Award (2018), the Dolores Shockley Award (ACNP 2018) and the
Alexander Glassman Award
(Columbia University 2021).
MindMed CEO Robert Barrow said,
"We are thrilled to welcome Dr. Oquendo to our Scientific Advisory
Board. Our goal is to revolutionize mental health and addiction
care and we want to make effective treatments accessible to broad
and diverse patient populations from across the globe. Dr.
Oquendo's extensive experience in psychiatry and pharmacology,
including her work with high risk patients, will be invaluable in
progressing all of our research and development efforts."
Dr. Oquendo added, "In view of the pharmacologic actions that
compounds like LSD and psilocybin share with putative anti-suicidal
drugs, this exciting avenue of investigation may lead to
discoveries of new approaches to this life-threatening
behavior."
MindMed's Scientific Advisory Board is composed of a diverse
group of members with expertise in psychiatry, neuroscience, and
clinical development. The Scientific Advisory Board leverages
decades of deep knowledge in biotech and psychiatry to guide
MindMed's development programs. Members represent institutions such
as Stanford University, University of Pennsylvania, University of
Rochester, Boston University, and Massachusetts General Hospital.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that seeks to discover, develop and deploy psychedelic-inspired
medicines and therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation
of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Although the Company believes that the expectations
reflected in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the
Company's profile on SEDAR at www.sedar.com and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-appoints-dr-maria-oquendo-to-its-scientific-advisory-board-301417453.html
SOURCE Mind Medicine (MindMed) Inc.